Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gaurav D. Shah
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
- Beta
- 0.50
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.73
Financials
Net Income
$123.21MEBITDA
$136.56MFree Cash Flow
$-39.62MEPS (diluted)
$1.08Shares Outstanding (diluted)
114.51M+1600.9%Operating Expenses
$46.92MCash & Debt
$283.75MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-223.12M | $-2.01 |
| 2024 | $0.00 | $-258.75M | $-2.73 |
| 2023 | $0.00 | $-245.59M | $-2.92 |
| 2022 | $0.00 | $-221.86M | $-3.26 |
| 2021 | $0.00 | $-169.07M | $-2.68 |
| 2020 | $0.00 | $-146.67M | $-2.52 |
| 2019 | $0.00 | $-83.23M | $-1.70 |
| 2018 | $0.00 | $-74.52M | $-1.89 |
| 2017 | $0.00 | $-29.50M | $-4.36 |
| 2016 | $0.00 | $-42.85M | $-6.41 |
| 2015 | $0.00 | $-67.98M | $-10.29 |
| 2014 | $0.00 | $-9.53M | $-4.53 |
| 2013 | $0.00 | $-7.62M | $-3.62 |
| 2012 | $0.00 | $-6.06M | $-2.88 |
Valuation
RCKThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+0.00%Social Signal Score
Mentions (6)
- Newszacks.com·19d ago·Positive
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Positive
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·55d ago·Positive
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
View source ↗ - Newsbusinesswire.com·56d ago·Positive
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened R
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.39 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$1.08 vs $0.86beat
- Thu, May 7$-0.42 vs $-0.41miss
- Thu, Feb 26$-0.38 vs $-0.42beat
- Thu, Nov 6$-0.45 vs $-0.48beat
- Thu, Aug 7$-0.59 vs $-0.57miss
- Thu, May 8$-0.56 vs $-0.59beat
Estimates and results for RCKT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RCKT officers and directors.
- Bought
- $69k
- Sold
- $989k
2 trades
33 trades
- Wilson Martinsold
- Wilson Martinsold
- Shah Gauravsold
- Shah Gauravsold
- Wilson Martinsold
- Stevens Christopher Jamessold
- Chaudhuri Sarbanisold
- Shah Gauravsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RCKT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.